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Treatment of locally advanced head and neck cancer remains a challenge because of
the head and neck complex anatomy and the tumor invasion to the adjacent organs
and/or metastases to the cervical nodes. Postoperative irradiation or concurrent chemora-
diation may lead to damage of radiosensitive structures such as the salivary glands,
mandible, cochlea, larynx, and pharyngeal muscles. Xerostomia, osteoradionecrosis, deaf-
ness, hoarseness of the voice, dysphagia, and aspiration remain serious complications
of head and neck irradiation and impair patient quality of life. Intensity-modulated and
image-guided radiotherapy by virtue of steep dose gradient and daily imaging may allow
for decreased radiation of the organs at risk for complication while preserving loco-regional
control.
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TREATMENT OF LOCALLY ADVANCED HEAD AND NECK
CANCER
Treatment of locally advanced head and neck cancer remains a
challenge because of the high rate of loco-regional failures and
the potential for serious complications following treatment. The
tumor frequently invades adjacent organs and/or regional neck
nodes. Standard of care has been either postoperative irradiation
or concurrent chemoradiation (1). Regardless of the modality
chosen, serious complications may occur because of the pres-
ence of radiosensitive organs such as the salivary glands, cochlea,
mandible, larynx, and pharyngeal muscles in the radiation field.
Xerostomia, deafness, osteoradionecrosis, dysphagia, weight loss,
chronic hoarse voice, and aspiration are potential long-term com-
plications of radiation treatment with conventional radiotherapy
techniques. Intensity-modulated radiotherapy (IMRT) has been
introduced to decrease the toxicity of irradiation because of the
steep dose gradient allowing for sparing of radiosensitive organs.
Randomized studies have demonstrated significant sparing of the
parotid glands following IMRT of head and neck cancer and
decreased severity of the xerostomia with improvement of patient
quality of life (QOL) (2, 3). However, a significant amount of nor-
mal tissues is still irradiated because the inclusion of the tumor
and areas at high risk for invasion with a large rim of normal
tissue called planning target volume or PTV, to avoid marginal
miss. Recently, image-guided radiotherapy (IGRT) by combining
the steep dose gradient of IMRT and daily imaging may poten-
tially improve further the toxicity of head and neck irradiation
because of the possibility of safe PTV reduction given the reduced
inter-fraction movement through daily imaging.
Significant reduction of spinal cord dose may be achieved with
IGRT compared to IMRT by a reduced PTV margin (4). However,
the flip side of IGRT is also the risk of under-dosing the tumor
if the target area is not adequately outlined. Thus, pre-treatment
imaging to meticulously delineate the tumor and areas at risk of
invasion is a critical component for the success of IGRT.
IMAGING STUDIES CRITICAL FOR IGRT PLANNING
Positron-emission tomography (PET) scan or PET-computed
tomography (PET-CT) allows accurate delineation of the tumor
and cervical lymph nodes that can be incorporated into the plan-
ning CT. PET-CT is superior to CT for tumor imaging because of
its ability to detect the tumor metabolic activity in addition to its
anatomic location. In a study of 102 unresectable head and neck
cancer, PET-CT significantly changed the staging and manage-
ment of these patients compared to CT alone (5). Twelve patients
had modifications of the radiotherapy planning following review
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of their PET-CT. In another study of 20 patients with oropha-
ryngeal cancers, the incorporation of PET-CT into radiotherapy
planning prevented marginal miss in two patients (6). The abil-
ity of PET-CT for better tumor delineation compared to CT for
radiotherapy planning was also corroborated in other studies (7,
8). Thus, PET-CT should be included in the planning for head and
neck IGRT.
Although PET-CT is the diagnostic imaging of choice for head
and neck cancer IGRT, magnetic resonance imaging (MRI) also
plays a critical role when there is suspicion of nerves infiltra-
tion, base of skull or parapharyngeal space invasion by the tumor
given its better soft tissue discrimination compared to CT. For
patients with nasopharyngeal cancer, MRI is complementary to
PET-CT because of the tumor location with high risks for intracra-
nial invasion through the skull base foramen and parapharyngeal
extension (9, 10). In addition head and neck MRI may also have
a prognostic value for survival after head and neck irradiation of
nasopharyngeal cancer (11).
IMAGE-GUIDED RADIOTHERAPY POTENTIAL FOR PAROTID
GLAND PRESERVATION
Xerostomia remains one of the most common complications of
head and neck cancer Irradiation and may severely affect the
QOL of patients. Xerostomia results from apoptosis of the aci-
nar glands secondary to radiation and its severity is proportional
to the radiation dose to the parotid glands (12).
Compared to the three-dimensional conformal radiotherapy
technique (3D-CRT), IMRT may significantly reduce radiation
dose to the parotid glands because of the steep dose gradient.
Mean dose to the parotids is usually kept around 26 Gy to allow
recovery of the saliva following head and neck irradiation. How-
ever, if only one parotid gland can be spared from radiation,
current recommendation is to keep mean parotid dose at 20 Gy or
lower (13). A recent study suggested that preservation of the con-
tralateral parotid gland may lead to improvement of patient QOL
following head and neck cancer irradiation. Among 31 patients
with head neck cancer treated with IMRT, there was significant
preservation of salivary flow and better QOL as measured by QOL
questionnaires if the contralateral parotid gland can be preserved
because of less sticky saliva (14). Preliminary experience suggests
that IGRT may preserve salivary function and QOL without com-
promising target coverage. In a study of 76 patients treated with
IGRT for head and neck cancer, excellent loco-regional control
was obtained as the gross tumor was treated to 70.5 Gy in 2.2–
2.3 Gy/fraction while most of the patients were able to preserve a
good QOL because of parotid preservation (15). In another study
of parotid preservation, IGRT can significantly decrease the mean
contralateral parotid gland dose to 14 Gy without compromising
target coverage, suggesting that IGRT may further improve patient
QOL compared to IMRT (16).
POTENTIAL OF IGRT FOR HEARING PRESERVATION
Hearing loss commonly occurred following concurrent head and
neck chemoradiation. A significant proportion of head and neck
patients had baseline hearing deficit prior to radiation related to
their age. Cisplatin can cause hearing loss which is dose-dependent
and may exacerbate the elderly patients hearing deficits. When
cisplatin is combined with radiotherapy, the hearing loss may
worsen because of the radiosensitization effects of cisplatin on
the normal cochlea cells. The threshold for hearing deficit ranges
from 10 to 13 Gy when radiotherapy is combined with chemother-
apy and affects mainly the high frequency range (>4,000 Hz) (17).
However, severe deafness may occur when cochlea radiation dose
exceeds 47 Gy because the low frequencies range (<3,000 Hz) is
then also affected (18). Deafness is a handicap and may lead to
social isolation and poor QOL. In addition, it may affect the patient
gainful employment because of the difficulty to communicate at
work. Thus, lowering cochlea dose below the threshold for hearing
deficit may preserve the patients’ hearing and conserve their QOL.
Compared to 3D-CRT, IMRT may decrease radiotherapy dose to
the cochlea and provide better hearing preservation (19). Mean
cochlea dose reported in the literature for patients with head and
neck cancer undergoing IMRT ranged from 16 to 55 Gy. Prelimi-
nary data for IGRT of head and neck cancer for cochlea sparing is
encouraging. In a study of 52 patients who had IGRT for locally
advanced head and neck cancer, mean cochlea dose was reduced
to 6–6.5 Gy which is below the threshold for radiotherapy damage
without compromising target volume coverage (20). Thus, hear-
ing preservation with IGRT is feasible and needs to be investigated
in future prospective studies of head and neck cancer.
POTENTIAL OF IGRT FOR MANDIBULAR SPARING
Osteoradionecrosis remains one of the most feared complications
of head and neck cancer irradiation because of its effect on patient
QOL. In severe cases of osteoradionecrosis unresponsive to con-
servative management, resection of the damaged bone may result
in severe alteration of speech, chewing, and swallowing. The risk
of radionecrosis is related to the volume of normal bone radiated
to high radiation dose. Damage of the microvasculature irrigat-
ing the mandible may lead to decreased blood flow, poor wound
healing, and ultimately necrosis. Mandibular radionecrosis usually
occurs when the mandible dose exceeds 66 Gy (21). The preva-
lence of osteoradionecrosis ranges from 5 to 7% in head and
neck cancer patients treated with the conventional fractionation
(1.8–2 Gy/fraction) and 3D-CRT. The risk of radionecrosis may be
reduced with IMRT because of the sharp dose gradient allowing
for reduction of the volume of normal bone radiated to a high
dose. The reported prevalence of osteoradionecrosis ranges from
1 to 5% depending on the anatomic site of the cancer as cancers
of the oral cavity usually require treating a large of volume of the
mandible to a high radiation dose (22, 23). The IGRT technique
may further decrease radiation dose to the mandible and thus the
risk of radionecrosis. In a study of 83 head and neck cancer patients
of various anatomic sites treated with IMRT (17) and IGRT (66),
only one patient developed radionecrosis (24). Thus, IGRT may
be a promising technique for mandibular preservation in future
clinical trials.
POTENTIAL OF IGRT TO PREVENT LARYNGEAL EDEMA IN
NON-LARYNGEAL AND NON-HYPOPHARYNGEAL HEAD AND
NECK CANCER
Laryngeal edema and resulting dysphonia commonly occur fol-
lowing head and neck cancer radiation when the laryngeal dose
exceeds 43.5 Gy (25). The dysphonia severity is proportional to the
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radiation dose and related on the abnormal cord vibrations caused
by the edema which may be persistent up to 72 months after radi-
ation (26). Chronic hoarseness of the voice may impair patient
QOL or affect their professional activity if the patient depends
on the quality of his voice to make a living. Laryngeal edema is
unavoidable when the tumor is located in the larynx or hypophar-
ynx because of the high radiation dose required for cure (70 Gy).
When the tumor is located in other anatomic sites, shielding of the
larynx with a midline block would significantly decrease radiation
dose to the larynx and prevent the risk of laryngeal edema. How-
ever, in the presence of cervical lymph nodes, a laryngeal shield
may under-dose the cervical lymph nodes leading to an increased
risk of regional recurrence. Whole field head and neck IMRT is
usually recommended in the presence of neck node metastases to
avoid geographic miss. Compared to whole field head and neck
IMRT, IGRT can significantly reduce radiation dose to the larynx
in patients with non-laryngeal and non-hypopharyngeal head and
neck cancers (27). Preliminary results suggest that IGRT may also
reduce the risk of laryngeal edema and effectively preserve patient
voice following head and neck radiation (28).
POTENTIAL OF IGRT TO REDUCE ASPIRATION RISK
FOLLOWING RADIATION FOR NON-LARYNGEAL AND
NON-HYPOPHARYNGEAL HEAD AND NECK CANCER
Aspiration is a life-threatening complication of a head and cancer
irradiation because of the risk of pneumonia and sepsis. Aspira-
tion commonly occurs following head and neck cancer irradiation
because of damage to the pharyngeal constrictor muscles. Aspi-
ration risk is proportional to radiation dose to the pharyngeal
muscles. Even though there are still controversies about which
pharyngeal muscles are critical for the development of aspiration,
32% of the patients developed aspiration when the dose to the
inferior pharyngeal muscles exceeds 52 Gy (29). Thus, patients
with laryngeal and hypopharyngeal cancer are at highest risk of
aspiration following head and neck cancer irradiation. However,
a high rate of aspiration is still observed following radiation of
non-laryngeal and non-hypopharyngeal head and neck cancers.
Aspiration rates ranged from 16 to 54% following non-laryngeal
and non-hypopharyngeal cancer irradiation with 3D-CRT and
whole field IMRT (30, 31). Whole field IGRT reduces signifi-
cantly the risk of aspiration for these patients. Only 2 out of
48 patients developed minimal aspiration which resolved with
swallowing therapy following IGRT for non-laryngeal and non-
hypopharyngeal head and neck cancer (32). Thus, IGRT is a
promising technique to reduce the risk of aspiration and to
improve patient QOL in head and neck cancer patients.
EFFECTIVENESS OF IGRT FOR LOCO-REGIONAL CONTROL IN
PATIENTS WITH HEAD AND NECK CANCERS
Preliminary clinical experiences of IGRT for head and neck cancers
have been very encouraging. Excellent loco-regional control and
survival have been achieved for various anatomic head and neck
cancer sites. In a study of 19 patients with locally advanced oral
cavity cancer who received postoperative irradiation with IGRT,
the 2-year survival and loco-regional control were 94 and 92%,
respectively (33). In another study of 28 patients who under-
went concurrent chemotherapy and IGRT for locally advanced
nasopharyngeal cancer, the 3-year survival and loco-regional con-
trol were respectively 83.5 and 88.4% respectively (34). Similar
high rates of loco-regional control were also observed for oropha-
ryngeal and laryngeal cancers (35, 36). Because of the small num-
ber of patients and the short follow-up, these studies should be
interpreted with caution but they may be helpful for the design of
future prospective studies of head and neck cancer IGRT.
CONCLUSION
Image-guided radiotherapy for head and neck cancer is a promis-
ing technique of radiation because of the potential for normal
organ sparing without compromise of target coverage. Prelim-
inary clinical results suggest that the dosimetric advantages of
IGRT may be translated into excellent loco-regional control for
patients with head and neck cancer. Further prospective studies
with a large number of patients should be performed to verify this
hypothesis.
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